Smith & Nephew jumps as hip and knee replacements in demand

  • Smith & Nephew PLC (LSEN) shares rose over 5% to top the early FTSE 100 leaderboard on Wednesday after the knee and hip replacer maintained its full-year 2025 guidance after seeing growth of 3.1% in underlying revenue for the first quarter. The performance was supported by recent product launches and continued operational improvements across its business lines, with total reported revenue up 1.6% to $1.4 billion after a negative foreign exchange, ongoing headwinds from China and one fewer trading day compared to the prior year.